Julphar grows, launches new corporate brand

Source: News Source

RAS AL KHAIMAH: Gulf Pharmaceutical Industries (Julphar) launched its new corporate brand, following the completion of a branding project that sought to asses its identity and image.

The branding project came about as the company continues to grow and assume a greater role in the global healthcare industry.

With biotechnology at the forefront of its strategy, the new corporate brand is meant to establish Julphar as one of the largest pharmaceutical manufacturers and distributors in the Middle East and North Africa (Mena) region that is based in Ras Al Khaimah where it started in 1980.

The growth and prevalence of this company presents a strong case to “communicate the right identity and image” as Julphar takes its next steps in the pharmaceutical world, elaborated Dr. Ayman Sahli, CEO of Julphar.

“Julphar is unanimous with quality,” said Dr. Sahli as he talked about the many and various accomplishments that Julphar has achieved at a roundtable media conference that was held on Monday at the Julphar premises in Ras Al Khaimah.

The new brand will have the current visual identity changed as well as more tightening of the brand system to achieve consistency of identity, image, and messages conveyed internally and externally, locally and globally, according to Dr. Sahli, and with 90 per cent of its products exported it appears that there is a definite need to define the way Julphar wants its public to view it.

This year, Julphar opened a new plant in Addis Ababa in Ehiopia in a step that reflected aggressive expansion plans to emerging markets. In the pipeline are two more plants in Algeria and Saudi Arabia to help meet increasing demand on medicines at affordable prices in there markets and neighboring ones.

Another accomplishment for the pharmaceutical giant is the inauguration of a $180 million state of the art diabetes plant in RAK, responsible for producing the raw material used to make insulin, allegedly enabling the UAE to become one of the top producers in the world. Currently, the company has a production capacity of 40 million vials per year, a quantity sufficient to meet demand on insulin in the region, according to Joseph Saldanha, General Manager, Julphar Diabetes.

 

“Everyone in the UAE knows about products imported from other parts of the world but few would know that our products are distributed to five continents,” said Dr. Sahli.